CVS Health Corporation (NYSE:CVS) is one of the best medical stocks to invest in according to billionaires. Morgan Stanley lifted the price target on CVS Health Corporation (NYSE:CVS) to $106 from $93 on May 14, maintaining an Overweight rating on the shares. CVS Health Corporation (NYSE:CVS) also received a rating update from Bernstein on May 13, with the firm lifting the price target on the stock to $106 from $94 and reiterating an Outperform rating on the shares.
The firm stated that it is continuing to see the company as having an attractive exposure to the Medicare Advantage turnaround, as well as potential for more stable earnings in its pharmacy and pharmacy benefit manager businesses post-PBM reform. It added that with the PBM bill and the first Federal Trade Commission settlement earlier this year, the firm considers the PBM reform as largely complete and a clearing event, driving less uncertainty around CVS Health Corporation’s (NYSE:CVS) turnaround.
CVS Health Corporation (NYSE:CVS) is a health solutions company that operates in four segments: healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other.
While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.